Is the Estrogen Controversy Over? Deconstructing the Women's Health Initiative Study: A Critical Evaluation of the Evidence
- 1 June 2005
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1052 (1) , 43-56
- https://doi.org/10.1196/annals.1347.004
Abstract
The Women's Health Initiative (WHI) hormone trials have been widely interpreted as demonstrating that combined menopausal hormone therapy (HT) fails to protect against—and may increase—cardiovascular disease (CVD), stroke, and dementia in menopausal women, regardless of whether initiated early in the menopause or later. This conclusion does not agree with results of large epidemiological studies showing protection by HT and by estrogen replacement alone (ET) against CVD and dementia. One possible reason for this inconsistency is that the epidemiologic data are confounded by “healthy user bias.” Another possible explanation is that most women in the observational studies initiated ET or HT at or near the menopausal transition, at which point there is little or no arterial injury, whereas, in the WHI studies, older women, averaging approximately 12 years postmenopausal, many of whom would have had significant asymptomatic atherosclerosis, were treated. Substantial data demonstrate atheropreventive effects of estrogen before vascular damage occurs, whereas adverse effects of oral estrogen on thrombosis and inflammation may predominate once complex atheromas are present. Similarly, the excess of dementia observed in older WHI women treated with oral conjugated estrogen could be due to cerebral thromboses (multi-infarct dementia). Given the uncertain relevance of the WHI (and other published randomized clinical trials) to initiation of HT in perimenopausal women, and its subsequent continuation for atheroprevention, new trials will be needed to resolve whether early intervention with estrogen may prevent CVD and/or dementia. The Kronos Early Estrogen Prevention Study (KEEPS), which began in mid-2005, is a randomized, controlled multicenter trial of HT in recently menopausal women. It will examine surrogate end points as well as risk factors for atherosclerosis.Keywords
This publication has 77 references indexed in Scilit:
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Effect of Estrogen Plus Progestin on Progression of Carotid Atherosclerosis in Postmenopausal Women With Heart DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Influence of 17β-oestradiol on blood pressure of postmenopausal women at high vascular riskJournal Of Hypertension, 2001
- 17β-estradiol inhibits oxidized low density lipoprotein-induced generation of reactive oxygen species in endothelial cellsLife Sciences, 2001
- Trends in the Incidence of Coronary Heart Disease and Changes in Diet and Lifestyle in WomenNew England Journal of Medicine, 2000
- Effects of Estrogen Replacement on the Progression of Coronary-Artery AtherosclerosisNew England Journal of Medicine, 2000
- Regression of Atherosclerosis in Female MonkeysArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Thrombosis and thrombolysis in unstable anginaThe American Journal of Cardiology, 1991
- The Risk of Breast Cancer after Estrogen and Estrogen–Progestin ReplacementNew England Journal of Medicine, 1989